Backing the companies that will define medicine's next decade.
Basil Health Ventures backs founders at the intersection of biology, data, and device innovation — from first check to clinical scale.
Basil Health Ventures backs founders at the intersection of biology, data, and device innovation — from first check to clinical scale.
Three sectors where we back founders from first check through clinical scale.
We back early-stage teams building clinical-grade software — remote monitoring, care coordination, AI-assisted diagnostics, and chronic disease management. Typical check: $5–15M led at Series A. Portfolio includes companies that have reached more than 1 million patients.
We invest at the earliest stage of the science — gene therapies, novel biologics, and computational drug discovery — and follow companies through clinical validation. Our partners evaluate the data themselves before making a commitment. Typical check: $5–20M led, with follow-on through Series B.
We back founders building closed-loop systems, smart implants, and biosensor platforms — device companies that are increasingly also software companies. Our partner Marcus Elliot brings 18 years of FDA experience directly to each deal, reducing regulatory risk from day one. Typical check: $5–25M led.
A focused process, built around clinical rigor and founder partnership.
We identify founders through clinical networks, research institutions, and accelerator partnerships. A significant share of our deal flow comes from MGH, Broad Institute, and MIT affiliates.
Deep scientific and commercial due diligence with our clinical advisory board. We don't outsource the science to consultants — our partners run the evaluation personally.
Active board membership, regulatory guidance, and strategic introductions. Our partners have collectively spent decades navigating the FDA, CMS reimbursement, and hospital procurement.
Follow-on capital and ecosystem access through Series B and beyond. We stay invested in the companies we believe in and help recruit the executive talent needed to scale from product to platform.
Combined portfolio valuation
Companies reached 1M+ patients
Portfolio IPOs since 2021